GT
SCLN

Glenmede Trust’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Glenmede Trust’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-86,200
Closed -$965K – 2911
2017
Q3 		$965K Sell
86,200
-218,873
-72% -$2.41M ﹤0.01% 769
2017
Q2 		$2.99M Hold
305,073
– – 0.01% 571
2017
Q1 		$2.99M Hold
305,073
– – 0.01% 571
2016
Q4 		$3.29M Hold
305,073
– – 0.02% 531
2016
Q3 		$3.13M Hold
305,073
– – 0.02% 540
2016
Q2 		$3.98M Sell
305,073
-107,093
-26% -$1.4M 0.02% 492
2016
Q1 		$4.53M Hold
412,166
– – 0.03% 448
2015
Q4 		$3.79M Hold
412,166
– – 0.03% 477
2015
Q3 		$2.86M Buy
412,166
+52,926
+15% +$453K 0.02% 515
2015
Q2 		$3.53M Buy
359,240
+9,850
+3% +$89.7K 0.03% 451
2015
Q1 		$3.1M Buy
349,390
+123,110
+54% +$981K 0.02% 506
2014
Q4 		$1.98M Buy
+226,280
New +$1.83M 0.02% 572

Glenmede Trust's SCLN Position: Q4 2017 in Review

Glenmede Trust sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 86,200 shares — an estimated $965K sold.

Glenmede Trust first reported a position in SCLN in Q4 2014 and held it in 12 quarters. The position peaked at $4.53M in Q1 2016. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

  • Glenmede Trust reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Glenmede Trust sold 86,200 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $965K.
  • Glenmede Trust first reported a position in Sciclone Pharmaceuticals Inc in Q4 2014 and held it in 12 quarters.
  • Glenmede Trust's Sciclone Pharmaceuticals Inc position peaked at $4.53M in Q1 2016.
  • 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on Glenmede Trust's 13F filing for Q4 2017, filed 15 Feb 2018.